LBPMedicine(SH:688393) Zheng Quan Zhi Xing·2025-08-21 10:22Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management, not exceeding RMB 140 million, ensuring that it does not affect the normal implementation of fundraising investment plans [1][5]. Summary by Sections 1. Basic Situation of Raised Funds - The company raised a total of RMB 713.27 million from its initial public offering (IPO) by issuing 23.34 million shares at a price of RMB 30.56 per share, with all funds received and stored in a dedicated account [1]. 2. Investment Project Situation - The planned use of raised funds includes a project focused on the application development of a tumor companion diagnostic technology platform, with a total project cost of RMB 491.65 million and an intended use of RMB 453.62 million from the raised funds [2]. 3. Cash Management of Temporarily Idle Raised Funds - The company plans to use up to RMB 140 million of temporarily idle raised funds for cash management, ensuring that it does not impact the normal progress of fundraising investment projects. The funds can be used in a rolling manner within the specified limit [2][5]. - The investment period for this cash management is valid for 12 months from the date of board approval [3]. 4. Implementation Method - The board has authorized the chairman to exercise investment decision-making rights and sign relevant documents within the approved limit and validity period, with the finance department responsible for implementation [4]. 5. Distribution of Cash Management Earnings - Earnings from cash management will belong to the company and will be managed according to regulatory requirements, with funds returned to the dedicated account upon maturity [4]. 6. Review Procedures - The board and supervisory board have approved the cash management proposal, confirming compliance with relevant regulations and ensuring that it does not conflict with the construction of fundraising investment projects [5][6].